BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 21281469)

  • 21. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation.
    Schlange T; Matsuda Y; Lienhard S; Huber A; Hynes NE
    Breast Cancer Res; 2007; 9(5):R63. PubMed ID: 17897439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205.
    Massoner P; Thomm T; Mack B; Untergasser G; Martowicz A; Bobowski K; Klocker H; Gires O; Puhr M
    Br J Cancer; 2014 Aug; 111(5):955-64. PubMed ID: 24992580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth.
    Matsuda Y; Schlange T; Oakeley EJ; Boulay A; Hynes NE
    Breast Cancer Res; 2009; 11(3):R32. PubMed ID: 19473496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel therapeutic drug for colon cancer: EpCAM scFv-truncated protamine (tp)-siRNA.
    Hao H; Zhen Y; Wang Z; Chen F; Xie X
    Cell Biol Int; 2013 Aug; 37(8):860-4. PubMed ID: 23576466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of nuclear EpICD in extrahepatic cholangiocarcinoma: association with β-catenin.
    Jachin S; Bae JS; Sung JJ; Park HS; Jang KY; Chung MJ; Kim DG; Moon WS
    Int J Oncol; 2014 Aug; 45(2):691-8. PubMed ID: 24888903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway.
    Ma X; Yan W; Dai Z; Gao X; Ma Y; Xu Q; Jiang J; Zhang S
    Drug Des Devel Ther; 2016; 10():1419-41. PubMed ID: 27143851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
    Richter CE; Cocco E; Bellone S; Bellone M; Casagrande F; Todeschini P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Int J Gynecol Cancer; 2010 Dec; 20(9):1440-7. PubMed ID: 21370592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast cancer-specific mutations in CK1epsilon inhibit Wnt/beta-catenin and activate the Wnt/Rac1/JNK and NFAT pathways to decrease cell adhesion and promote cell migration.
    Foldynová-Trantírková S; Sekyrová P; Tmejová K; Brumovská E; Bernatík O; Blankenfeldt W; Krejcí P; Kozubík A; Dolezal T; Trantírek L; Bryja V
    Breast Cancer Res; 2010; 12(3):R30. PubMed ID: 20507565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nuclear signalling by tumour-associated antigen EpCAM.
    Maetzel D; Denzel S; Mack B; Canis M; Went P; Benk M; Kieu C; Papior P; Baeuerle PA; Munz M; Gires O
    Nat Cell Biol; 2009 Feb; 11(2):162-71. PubMed ID: 19136966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer.
    Wenqi D; Li W; Shanshan C; Bei C; Yafei Z; Feihu B; Jie L; Daiming F
    J Cancer Res Clin Oncol; 2009 Sep; 135(9):1277-85. PubMed ID: 19294417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low.
    Ring A; Mineyev N; Zhu W; Park E; Lomas C; Punj V; Yu M; Barrak D; Forte V; Porras T; Tripathy D; Lang JE
    Oncotarget; 2015 Dec; 6(42):44623-34. PubMed ID: 26556851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between overexpression of EpCAM in prostate tissues and genesis of androgen-dependent prostate cancer.
    Xu Y; Zhao H; Hou J
    Tumour Biol; 2014 Jul; 35(7):6695-700. PubMed ID: 24705864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-449b-5p suppresses the growth and invasion of breast cancer cells via inhibiting CREPT-mediated Wnt/β-catenin signaling.
    Jiang J; Yang X; He X; Ma W; Wang J; Zhou Q; Li M; Yu S
    Chem Biol Interact; 2019 Apr; 302():74-82. PubMed ID: 30738779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.
    Yamashita T; Forgues M; Wang W; Kim JW; Ye Q; Jia H; Budhu A; Zanetti KA; Chen Y; Qin LX; Tang ZY; Wang XW
    Cancer Res; 2008 Mar; 68(5):1451-61. PubMed ID: 18316609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Downregulation of Dickkopf-1 is responsible for high proliferation of breast cancer cells via losing control of Wnt/beta-catenin signaling.
    Zhou XL; Qin XR; Zhang XD; Ye LH
    Acta Pharmacol Sin; 2010 Feb; 31(2):202-10. PubMed ID: 20139903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells.
    Wang K; Ma Q; Ren Y; He J; Zhang Y; Zhang Y; Chen W
    Oncol Rep; 2007 Jan; 17(1):89-96. PubMed ID: 17143483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
    Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
    PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC.
    Preet R; Mohapatra P; Das D; Satapathy SR; Choudhuri T; Wyatt MD; Kundu CN
    Carcinogenesis; 2013 Feb; 34(2):277-86. PubMed ID: 23129580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of the specificity and selectivity of anti-EpCAM antibodies in breast cancer cell lines.
    Sterzynska K; Kempisty B; Zawierucha P; Zabel M
    Folia Histochem Cytobiol; 2012; 50(4):534-41. PubMed ID: 23264216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.